Korean J Urol.  2013 Nov;54(11):783-790.

Efficacy of an Enuresis Alarm, Desmopressin, and Combination Therapy in the Treatment of Saudi Children With Primary Monosymptomatic Nocturnal Enuresis

• Ahmed AF
• Amin MM
• Ali MM
• Shalaby EA

Abstract

PURPOSE
We evaluated and compared the effectiveness of an enuresis alarm, desmopressin medication, and their combination in the treatment of Saudi children with primary monosymptomatic nocturnal enuresis (PMNE).
MATERIALS AND METHODS
A total of 136 children with PMNE were randomly assigned to receive an enuresis alarm alone (EA group, n=45), desmopressin alone (D group, n=46), or a combination of both (EA/D group, n=45). Patients were followed weekly during treatment and for 12 weeks after treatment withdrawal.
RESULTS
During treatment, wetting frequencies were significantly reduced in all groups and remained significantly lower than pretreatment values until the end of follow-up. In the D and EA/D groups, an immediate reduction in wetting frequencies was observed, whereas a longer time was required to reach a significant reduction in the EA group. The full and partial response rates were 13.3% and 37.8% in the EA group, 26.1% and 43.5% in the D group, and 40.0% and 33.3% in the EA/D group. A significant difference was observed only between the EA and EA/D groups (p=0.025). Relapse rates were higher in the D group (66.6%) than in the EA (16.6%) and EA/D (33.3%) groups. A significant difference was observed between the D and EA groups only (p=0.019).
CONCLUSIONS
Desmopressin, an enuresis alarm, and combined therapy are effective in the treatment of Saudi children with PMNE. Desmopressin produced an immediate effect but relapses were common. The enuresis alarm provided gradual effects that persisted posttreatment. The combined therapy was superior to the alarm in achieving an immediate response; however, its effect was not better than that of the alarm long term.

Keyword

Combined modality therapy; Nocturnal enuresis; Treatment efficacy

MeSH Terms

Child*
Combined Modality Therapy
Deamino Arginine Vasopressin*
Enuresis*
Follow-Up Studies
Humans
Nocturnal Enuresis*
Recurrence
Treatment Outcome
Deamino Arginine Vasopressin

Figure

• 

  FIG. 1 The flow diagram.

• 

  FIG. 2 Box-and-whisker plot. Wetting frequencies, within-group, at different time points were compared with pretreatment values by using paired t-tests. A significant reduction in wet nights was observed between baseline, end of treatment, and end of follow-up in the 3 groups; p<0.0001 in all groups except between end of treatment and end of follow-up in group 2 (p=0.047).

• 

  FIG. 3 Wetting frequencies were analyzed week by week in the 3 groups by using paired and independent t-tests. Baseline (week 1); treatment period (weeks 2-13); follow-up period (weeks 14-25). (Δ), time of significant reduction of wet nights in group 1 (p=0.0001); (Ω), time of significant reduction in wet nights in group 2 (p=0.0001); (†), time of significant reduction of wet nights in group 3 (p<0.0001); (Φ), time of significant rebound in group 1 (p=0.0074); (I), time of significant rebound in group 2 (p=0.0009); (O), time of significant rebound in group 3 (p=0.0047); (*), p<0.05, intergroup comparison of group 1 vs. 2; (‡), p<0.05, intergroup comparison of group 1 vs. 3; (#), p <0.05, intergroup comparison of group 2 vs. 3.

Reference

1. Yamamoto LG, Inaba AS, Okamoto JK, Patrinos ME, Yamashiroya VK, editors. Enuresis. Case based pediatrics for medical students and residents [monograph on the Internet]. Honolulu: Department of Pediatrics, University of Hawaii John A Burns School of Medicine;c2004. cited 2010 May 28. 5–28. Available from: http://www.hawaii.edu/medicine/pediatrics/pedtext/.

2. Butler RJ, Golding J, Northstone K. ALSPAC Study Team. Nocturnal enuresis at 7.5 years old: prevalence and analysis of clinical signs. BJU Int. 2005; 96:404–410.

3. Ozden C, Ozdal OL, Altinova S, Oguzulgen I, Urgancioglu G, Memis A. Prevalence and associated factors of enuresis in Turkish children. Int Braz J Urol. 2007; 33:216–222.

4. Butler RJ, Heron J. The prevalence of infrequent bedwetting and nocturnal enuresis in childhood: A large British cohort. Scand J Urol Nephrol. 2008; 42:257–264.

5. Butler RJ. Impact of nocturnal enuresis on children and young people. Scand J Urol Nephrol. 2001; 35:169–176.

6. Longstaffe S, Moffatt ME, Whalen JC. Behavioral and self-concept changes after six months of enuresis treatment: a randomized, controlled trial. Pediatrics. 2000; 105(4 Pt 2):935–940.

7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington, DC: American Psychiatry Press;1994.

8. Hjalmas K, Arnold T, Bower W, Caione P, Chiozza LM, von Gontard A, et al. Nocturnal enuresis: an international evidence based management strategy. J Urol. 2004; 171(6 Pt 2):2545–2561.

9. Wille S. Comparison of desmopressin and enuresis alarm for nocturnal enuresis. Arch Dis Child. 1986; 61:30–33.

10. Bradbury MG, Meadow SR. Combined treatment with enuresis alarm and desmopressin for nocturnal enuresis. Acta Paediatr. 1995; 84:1014–1018.

11. Leebeek-Groenewegen A, Blom J, Sukhai R, Van Der Heijden B. Efficacy of desmopressin combined with alarm therapy for monosymptomatic nocturnal enuresis. J Urol. 2001; 166:2456–2458.

12. Sukhai RN, Mol J, Harris AS. Combined therapy of enuresis alarm and desmopressin in the treatment of nocturnal enuresis. Eur J Pediatr. 1989; 148:465–467.

13. Fai-Ngo Ng C, Wong SN. Hong Kong Childhood Enuresis Study Group. Comparing alarms, desmopressin, and combined treatment in Chinese enuretic children. Pediatr Nephrol. 2005; 20:163–169.

14. Van Leerdam FJ, Blankespoor MN, Van Der Heijden AJ, Hirasing RA. Alarm treatment is successful in children with day- and night-time wetting. Scand J Urol Nephrol. 2004; 38:211–215.

15. Butler RJ, Robinson JC. Alarm treatment for childhood nocturnal enuresis: an investigation of within-treatment variables. Scand J Urol Nephrol. 2002; 36:268–272.

16. Nevéus T, von Gontard A, Hoebeke P, Hjalmas K, Bauer S, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society. J Urol. 2006; 176:314–324.

17. Husmann DA. Enuresis. Urology. 1996; 48:184–193.

18. Lyon C, Schnall J. What is the best treatment for nocturnal enuresis in children? J Fam Pract. 2005; 54:905–906. 909

19. Butler RJ, Holland P, Gasson S, Norfolk S, Houghton L, Penney M. Exploring potential mechanisms in alarm treatment for primary nocturnal enuresis. Scand J Urol Nephrol. 2007; 41:407–413.

20. Oredsson AF, Jorgensen TM. Changes in nocturnal bladder capacity during treatment with the bell and pad for monosymptomatic nocturnal enuresis. J Urol. 1998; 160:166–169.

21. Butler RJ, Gasson SL. Enuresis alarm treatment. Scand J Urol Nephrol. 2005; 39:349–357.

22. Adersson KE, Appell R, Cardozo L, Chapple C, Drutz H, Fourcroy J, et al. Pharmacological treatment of urinary incontinence. In : Abrams P, Cardozo L, Wein A, Khoury S, editors. Incontinence. 3rd International Consultation on Incontinence; 2004 June 26-29; Monaco. Plymouth: Plymbridge Distributors;2005. p. 809–854.

23. Lottmann H, Froeling F, Alloussi S, El-Radhi AS, Rittig S, Riis A, et al. A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis. Int J Clin Pract. 2007; 61:1454–1460.

24. Wolfish NM, Barkin J, Gorodzinsky F, Schwarz R. The Canadian Enuresis Study and Evaluation: short- and long-term safety and efficacy of an oral desmopressin preparation. Scand J Urol Nephrol. 2003; 37:22–27.

25. Robson WL, Leung AK, Norgaard JP. The comparative safety of oral versus intranasal desmopressin for the treatment of children with nocturnal enuresis. J Urol. 2007; 178:24–30.

26. Robson WL, Norgaard JP, Leung AK. Hyponatremia in patients with nocturnal enuresis treated with DDAVP. Eur J Pediatr. 1996; 155:959–962.

27. Monda JM, Husmann DA. Primary nocturnal enuresis: a comparison among observation, imipramine, desmopressin acetate and bed-wetting alarm systems. J Urol. 1995; 154(2 Pt 2):745–748.

28. Yeung CK, Sit FK, To LK, Chiu HN, Sihoe JD, Lee E, et al. Reduction in nocturnal functional bladder capacity is a common factor in the pathogenesis of refractory nocturnal enuresis. BJU Int. 2002; 90:302–307.

29. Burgu B, Gokce MI, Gucuk A, Soygur T. Prospective evaluation of factors affecting the response and relapse rates to desmopressin therapy in male monosymptomatic enuretic adults. Urology. 2009; 74:915–919.